Date: 2013-06-04

Type of information:

Compound: therapies targeting ZnT8

Company: Mellitech (France) Janssen Pharmaceuticals - J&J (USA)

Therapeutic area: Metabolic diseases

Type agreement: R&D

Action mechanism:

Disease: metabolic diseases


* On June 24th, 2013, Mellitech SAS, a biopharmaceutical company pioneering innovative approaches to the selective modulation of the ZnT8 target, a zinc transporter involved in the insulin secretion pathway and in various metabolic diseases,  has entered into a collaboration agreement with Janssen Pharmaceuticals, Inc. to discover, develop and commercialize therapies targeting ZnT8 for the treatment of metabolic diseases.
Mellitech is a spin-out from the CEA and the University of Joseph Fourier in Grenoble. The company is a leading player in the biology of ZnT8, a key pancreatic protein that enables the excretion of insulin from the beta cell. Focused on the application of ZnT8 science to diabetes, Mellitech is pursuing a program of discovery and development of treatments covering both type 1 and type 2 diabetes, and of an agent for imaging the functional beta cell mass.

Financial terms: Under the terms of the agreement, Janssen Pharmaceuticals will have worldwide commercialization rights to any products that may be developed as a result of the collaboration. Mellitech is eligible to receive development milestone payments as well as royalty payments on global sales. Further details of the financial terms were not disclosed.

Latest news:

Is general: Yes